(Brazikumab)Biosimilar Reference Antibody-GS40097 新品

货号：GS40097

Brazikumab is a humanized monoclonal antibody designed to specifically target the p19 subunit of interleukin-23 (IL-23). It functions as an antagonist by binding to IL-23p19, thereby blocking its interaction with the IL-23 receptor complex. This inhibits the downstream signaling of IL-23, a key cytokine that drives the differentiation, expansion, and maintenance of pathogenic T helper 17 (Th17) cells. It has been primarily investigated as a potential therapeutic for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD), representing a strategy to target a specific pathway within the broader IL-12/IL-23 axis implicated in inflammatory bowel disease (IBD) pathogenesis.